ScreenerHero

ELVN Enliven Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · enliventherapeutics.com
41.36USD-2.43%Mkt Cap: 3.03B $P/E: —

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap3.03B USD
Enterprise Value2.21B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-103.69M USD
Revenue/Share—
Last Price41.36 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees67
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-18.01
PEG—
EV/EBITDA-17.80
EV/Revenue—
P/S—
P/B3.47
EPS (TTM)-1.67
EPS (Forward)-2.35
52W Range
14.7956% of range62.32
52W High62.32 USD
52W Low14.79 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-22.56%
ROA-21.78%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-70.30M USD
CapEx (TTM)158.00K USD
FCF Margin—
FCF Yield-1.49%
Net Debt-893.65M USD
Net Debt/EBITDA7.19
Balance Sheet
Debt/Equity0.00
Current Ratio64.07
Quick Ratio63.21
Book Value/Sh12.22 USD
Cash/Share12.22 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)73.67 USD
Upside (mean)+78.1%
Target Range64.00 USD – 82.00 USD
64.00+78.1% to mean82.00
# Analysts12
Ownership
Shares Out.73.27M
Float60.52M
Insiders6.22%
Institutions114.10%
Short Interest
Short Ratio9.8d
Short % Float16.95%
Short % Out.11.77%
Shares Short8.62M
Short (prev mo.)8.26M
Technical
SMA 5054.95 (-24.7%)
SMA 20040.56 (+2.0%)
Beta0.34
S&P 52W Chg16.45%
Avg Vol (30d)1.30M
Avg Vol (10d)1.07M
Technical Indicators
RSI (14)23.0
MACD-3.3018
MACD Signal-2.7696
MACD Hist.-0.5322
BB Upper59.20 USD
BB Middle48.92 USD
BB Lower38.65 USD
BB Width42.01%
ATR (14)2.230 USD
Vol Ratio (20d)0.96x